Tandem Therapeutics

Tandem Therapeutics is a biotechnology company focused on developing therapies for fibrosis-driven diseases. The company leverages over 15 years of interdisciplinary research to create first-in-class treatments by understanding protein-protein interactions and matrix mechanobiology. Operating in the pharmaceutical and MedTech sectors, Tandem Therapeutics serves clients in the healthcare industry, including hospitals and research institutions. The business model revolves around the discovery and development of novel therapeutic compounds, with revenue generated through partnerships, licensing agreements, and potential commercialization of their therapies. The company's scientific foundation is built on the original discoveries made in the laboratory of Professor Viola Vogel at ETH Zurich, emphasizing the role of the extracellular matrix in disease progression. Tandem Therapeutics aims to address unmet medical needs by targeting the underlying mechanisms of fibrosis, offering potential breakthroughs in treatment options.

Keywords: fibrosis, therapies, protein interactions, extracellular matrix, biotechnology, healthcare, pharmaceutical, MedTech, disease modeling, peptide chemistry